Christopher Logothetis

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. ncbi request reprint Bortezomib as a potential treatment for prostate cancer
    Christos N Papandreou
    Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Cancer Res 64:5036-43. 2004
  2. ncbi request reprint Early predicted time to normalization of tumor markers predicts outcome in poor-prognosis nonseminomatous germ cell tumors
    Karim Fizazi
    Genito Urinary Group of the French Federation of Cancer Centers, Paris, France
    J Clin Oncol 22:3868-76. 2004
  3. ncbi request reprint Clinical and biomarker correlates of androgen-independent, locally aggressive prostate cancer with limited metastatic potential
    Vasily J Assikis
    Department of Genitourinary Medical Oncology, The University of Texas, M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 10:6770-8. 2004
  4. ncbi request reprint High efficacy of docetaxel with and without androgen deprivation and estramustine in preclinical models of advanced prostate cancer
    Karim Fizazi
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    Anticancer Res 24:2897-903. 2004
  5. doi request reprint Molecular classification of prostate cancer progression: foundation for marker-driven treatment of prostate cancer
    Christopher J Logothetis
    Departments of 1Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Discov 3:849-61. 2013
  6. doi request reprint Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised tri
    Christopher J Logothetis
    University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Lancet Oncol 13:1210-7. 2012
  7. pmc Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone
    Eleni Efstathiou
    Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Unit 1374, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 30:637-43. 2012
  8. pmc Candidate pathways and genes for prostate cancer: a meta-analysis of gene expression data
    Ivan P Gorlov
    Department of Genitourinary Medical Oncology, The University of Texas M, Anderson Cancer Center, Houston, TX, USA
    BMC Med Genomics 2:48. 2009
  9. pmc Prioritizing genes associated with prostate cancer development
    Ivan P Gorlov
    Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    BMC Cancer 10:599. 2010
  10. doi request reprint Abiraterone acetate
    Christopher J Logothetis
    Department of Genitourinary Medical Oncology, MD Anderson Cancer Center, The University of Texas, Houston, Texas 77030, USA
    Nat Rev Drug Discov 10:573-4. 2011

Research Grants

  1. University of Texas SPORE in Prostate Cancer
    Christopher Logothetis; Fiscal Year: 2007

Detail Information

Publications91

  1. ncbi request reprint Bortezomib as a potential treatment for prostate cancer
    Christos N Papandreou
    Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Cancer Res 64:5036-43. 2004
    ..This Phase I trial and preclinical studies support additional testing of bortezomib in combination with radiation or chemotherapy for androgen-independent prostate cancer...
  2. ncbi request reprint Early predicted time to normalization of tumor markers predicts outcome in poor-prognosis nonseminomatous germ cell tumors
    Karim Fizazi
    Genito Urinary Group of the French Federation of Cancer Centers, Paris, France
    J Clin Oncol 22:3868-76. 2004
    ....
  3. ncbi request reprint Clinical and biomarker correlates of androgen-independent, locally aggressive prostate cancer with limited metastatic potential
    Vasily J Assikis
    Department of Genitourinary Medical Oncology, The University of Texas, M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 10:6770-8. 2004
    ..The purpose of this study was to evaluate the expression of selected biomarkers to characterize this subset of prostate cancer patients...
  4. ncbi request reprint High efficacy of docetaxel with and without androgen deprivation and estramustine in preclinical models of advanced prostate cancer
    Karim Fizazi
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    Anticancer Res 24:2897-903. 2004
    ..To assess the activity of docetaxel in combination with hormonal therapy in preclinical models of prostate cancer...
  5. doi request reprint Molecular classification of prostate cancer progression: foundation for marker-driven treatment of prostate cancer
    Christopher J Logothetis
    Departments of 1Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Discov 3:849-61. 2013
    ..We use this model to discuss how integrating clinical and basic understanding of prostate cancer will lead to better implementation of molecularly targeted therapeutics and improve patient survival. ..
  6. doi request reprint Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised tri
    Christopher J Logothetis
    University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Lancet Oncol 13:1210-7. 2012
    ....
  7. pmc Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone
    Eleni Efstathiou
    Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Unit 1374, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 30:637-43. 2012
    ..This study aimed to evaluate androgen signaling in bone marrow-infiltrating cancer and testosterone in blood and bone marrow and to correlate with clinical observations...
  8. pmc Candidate pathways and genes for prostate cancer: a meta-analysis of gene expression data
    Ivan P Gorlov
    Department of Genitourinary Medical Oncology, The University of Texas M, Anderson Cancer Center, Houston, TX, USA
    BMC Med Genomics 2:48. 2009
    ..Suppression of integrin expression driven by integrin-mediated cell death leads to increased cell proliferation and motility and increased tumor malignancy...
  9. pmc Prioritizing genes associated with prostate cancer development
    Ivan P Gorlov
    Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    BMC Cancer 10:599. 2010
    ..Our working hypothesis was that combining meta-analyses on different but overlapping steps of prostate tumorigenesis will improve identification of genes associated with prostate cancer development...
  10. doi request reprint Abiraterone acetate
    Christopher J Logothetis
    Department of Genitourinary Medical Oncology, MD Anderson Cancer Center, The University of Texas, Houston, Texas 77030, USA
    Nat Rev Drug Discov 10:573-4. 2011
    ....
  11. ncbi request reprint Docetaxel in the management of advanced or metastatic urothelial tract cancer
    Christopher Logothetis
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Oncology (Williston Park) 16:107-11. 2002
    ..Randomizedphase III trials of a docetaxel-containing regimen in comparison with established regimens are ongoing, and additional studies are warranted to determine if overall long-term survival of TCCpatients can be improved...
  12. doi request reprint Understanding the biology of bone metastases: key to the effective treatment of prostate cancer
    Christopher J Logothetis
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Clin Cancer Res 14:1599-602. 2008
    ..g., docetaxel/imatinib or thalidomide) have been done. Analyses of the specimens from these trials provided support of our hypothesis and future development of diagnosis and therapy strategies...
  13. ncbi request reprint Foundation for the integration of biologically based therapy in the management of prostate cancer
    Christopher J Logothetis
    Department of Genitourinary Medical Oncology, The University of Texas, M D Anderson Cancer Center, Houston, Texas 77030, USA
    Prostate 57:32-8. 2003
    ..It is unlikely that any single agent or modality will successfully control PCa. It is hoped that the classification and trial designs we propose will facilitate the application of integrated treatment and prevention strategies...
  14. ncbi request reprint Osteoblasts in prostate cancer metastasis to bone
    Christopher J Logothetis
    Department of Genitourinary Oncology, University of Texas, M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA
    Nat Rev Cancer 5:21-8. 2005
    ..The interaction between host cells and metastatic cancer cells is an important component of organ-specific cancer progression. How can this knowledge lead to the development of more effective therapies?..
  15. ncbi request reprint Targeting platelet-derived growth factor receptor on endothelial cells of multidrug-resistant prostate cancer
    Sun Jin Kim
    Department of Cancer Biology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Natl Cancer Inst 98:783-93. 2006
    ..Because tumor cells and tumor-associated endothelial cells express activated PDGFR, the primary target for imatinib has been unclear...
  16. ncbi request reprint Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancer
    Paul Mathew
    Department of Genitourinary Medical Oncology, Unit 427, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 22:3323-9. 2004
    ..Our goals were to (1) evaluate the toxicity and maximum-tolerated dose of docetaxel with imatinib, and (2) evaluate the decline of prostate-specific antigen (PSA) induced by imatinib alone, and imatinib and docetaxel...
  17. ncbi request reprint Randomized, multicenter, phase II trial of two multicomponent regimens in androgen-independent prostate cancer
    Randall Millikan
    Genitourinary Medical Oncology Department, University of Texas M D Anderson Cancer Center, Houston, TX 77040 4009, USA
    J Clin Oncol 21:878-83. 2003
    ..We used a randomized phase II design to evaluate and compare two such regimens. Patients were accrued primarily in the community setting...
  18. pmc Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-gamma levels in both nonmalignant and malignant prostate tissues
    Hong Chen
    Department of Genitourinary Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Proc Natl Acad Sci U S A 106:2729-34. 2009
    ..These data should be taken into consideration for evaluation of efficacy as well as immune-related adverse events associated with anti-CTLA-4 therapy...
  19. ncbi request reprint Adaptive therapy for androgen-independent prostate cancer: a randomized selection trial of four regimens
    Peter F Thall
    Department of Biostatistics, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Natl Cancer Inst 99:1613-22. 2007
    ..With the goal of efficiently selecting promising regimens for more advanced trials, we conducted a randomized selection trial of four regimens to identify promising treatments for androgen-independent prostate cancer...
  20. ncbi request reprint A comprehensive assessment of p53-responsive genes following adenoviral-p53 gene transfer in Bcl-2-expressing prostate cancer cells
    Kevin B Spurgers
    Department of Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Oncogene 23:1712-23. 2004
    ..These results document a number of potential p53 targets and mediators of therapeutically relevant genotoxic stress. The findings further suggest that bcl-2 may inhibit cell death at multiple points downstream of p53 activation...
  21. ncbi request reprint Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate
    Christos N Papandreou
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 20:3072-80. 2002
    ..To determine the activity and toxicity of doxorubicin in combination with cisplatin and etoposide in patients with small-cell prostate carcinoma (SCPCa) and to characterize the clinicopathologic features of SCPCa...
  22. pmc Androgen receptor-negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms
    Zhi Gang Li
    Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030 4009, USA
    J Clin Invest 118:2697-710. 2008
    ..Androgen receptor-null cells may contribute to the castration-resistant osteoblastic progression of prostate cancer cells in bone and provide a preclinical model for studying therapies that target these cells...
  23. pmc Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer
    Dimitra Tsavachidou
    Department of Systems Biology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Natl Cancer Inst 101:306-20. 2009
    ....
  24. ncbi request reprint Inhibition of Mxi1 suppresses HIF-2alpha-dependent renal cancer tumorigenesis
    Chun Chui Tsao
    Department of Genitourinary Medical Oncology, MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Biol Ther 7:1619-27. 2008
    ..Compared to Mxi1-proficient tumors, Mxi1-deficient tumors display reduced cellular proliferation. These results establish Mxi1 as an important downstream target of HIF that contributes to pVHL-deficient renal cancer tumorigenesis...
  25. ncbi request reprint Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts
    Karim Fizazi
    Departments of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 9:2587-97. 2003
    ....
  26. ncbi request reprint Treatment of refractory urothelial carcinoma with alternating paclitaxel, methotrexate, cisplatin (TMP) and 5-fluorouracil, alpha-interferon, cisplatin (FAP)
    Shi Ming Tu
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Urol Oncol 21:342-8. 2003
    ..Furthermore, the complicated dosing schedule and toxic effects of the regimen precluded its routine use in the treatment of urothelial carcinoma...
  27. ncbi request reprint Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases
    Hisanori Uehara
    Department of Cancer Biology, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    J Natl Cancer Inst 95:458-70. 2003
    ..We examined the effects of STI571, given alone or with paclitaxel (Taxol), on tumor growth in a mouse model of prostate cancer metastasis...
  28. ncbi request reprint Cystoprostatectomy for effective palliation of symptomatic bladder invasion by prostate cancer
    Dan Leibovici
    Departments of Urology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    J Urol 174:2186-90. 2005
    ..We evaluated the palliative effect of cystoprostatectomy (CP) for palliating pelvic symptoms in patients with bladder invasion by prostate cancer...
  29. doi request reprint Dasatinib: a potent SRC inhibitor in clinical development for the treatment of solid tumors
    John Araujo
    Genitourinary Center, M D Anderson Cancer Centre, Houston, TX 77030, USA
    Cancer Treat Rev 36:492-500. 2010
    ..Future clinical trials will further assess the clinical value of SRC inhibition with dasatinib...
  30. ncbi request reprint Combination docetaxel and platelet-derived growth factor receptor inhibition with imatinib mesylate in prostate cancer
    Paul Mathew
    University of Texas M D Anderson Cancer Center, Department of Genitourinary Medical Oncology, Houston, 77030, USA
    Semin Oncol 31:24-9. 2004
    ..Clinical and translational data from these studies are likely to provide additional insights into the role of imatinib in combination therapy for prostate cancer...
  31. ncbi request reprint Initial modulation of the tumor microenvironment accounts for thalidomide activity in prostate cancer
    Eleni Efstathiou
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 13:1224-31. 2007
    ..We did a preoperative study to test the hypothesis that thalidomide, an active agent in metastatic disease, is a modulator of the tumor microenvironment...
  32. ncbi request reprint Phase II trial of cyclophosphamide, vincristine, and dexamethasone in the treatment of androgen-independent prostate carcinoma
    Danai D Daliani
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 97:561-7. 2003
    ....
  33. doi request reprint Expression of hedgehog pathway components in prostate carcinoma microenvironment: shifting the balance towards autocrine signalling
    Vassiliki Tzelepi
    Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77230, USA
    Histopathology 58:1037-47. 2011
    ..The aim of this study was to elucidate the cell-type partitioned expression of the Hh pathway biomarkers in the non-neoplastic and tumour microenvironments and to correlate it with the grade and stage of prostate cancer...
  34. ncbi request reprint Employing the treatment-free interval of intermittent androgen ablation to screen candidate prostate cancer therapies
    Shifeng Mao
    Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 3721, USA
    Prostate 67:1677-85. 2007
    ....
  35. ncbi request reprint Phase III trial of fluorouracil, interferon alpha-2b, and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic or unresectable urothelial cancer
    Arlene O Siefker-Radtke
    Center for Genitourinary Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 20:1361-7. 2002
    ..The purpose of this study was to compare the response rates and overall survival of patients with metastatic or unresectable urothelial cancer treated with these two chemotherapy regimens...
  36. pmc A secreted isoform of ErbB3 promotes osteonectin expression in bone and enhances the invasiveness of prostate cancer cells
    Nanyue Chen
    Department of Molecular Pathology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Cancer Res 67:6544-8. 2007
    ..Thus, p45-sErbB3 may mediate the bidirectional interactions between prostate cancer cells and bone via osteonectin...
  37. ncbi request reprint Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer
    Christos N Papandreou
    The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 0427, Houston, TX 77030, USA
    J Clin Oncol 22:2108-21. 2004
    ....
  38. ncbi request reprint The case for a biologically based classification of prostate cancer
    Christopher J Logothetis
    Department of Genitourinary Medical Oncology, University of Texas M D Anderson Center, Houston, TX 77030, USA
    Semin Oncol 30:562-6. 2003
    ..The understanding of the clinical biology and the development of a classification based on relevant clinical and biological features is central to therapy development...
  39. ncbi request reprint Changes in serum proteomic patterns by presurgical alpha-tocopherol and L-selenomethionine supplementation in prostate cancer
    Jeri Kim
    Department of Genitourinary Medical Oncology, University of Massachusetts Medical School, Lazare Research Building, Room 504, 364 Plantation Street, Worcester, MA 01605 2324, USA
    Cancer Epidemiol Biomarkers Prev 14:1697-702. 2005
    ..To determine the effects of selenium and vitamin E in blood and prostate tissue, we undertook a preoperative feasibility study complementary to the currently ongoing Selenium and Vitamin E Cancer Prevention Trial...
  40. ncbi request reprint Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts
    Simon Williams
    Department of Cancer Biology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Mol Cancer Ther 2:835-43. 2003
    ..Together, our results confirm that bortezomib is active in preclinical models of human prostate cancer, but its effects on apoptosis versus angiogenesis are cell type dependent...
  41. ncbi request reprint Is there a role for surgery in the management of metastatic urothelial cancer? The M. D. Anderson experience
    Arlene O Siefker-Radtke
    Center for Genitourinary Oncology and Department of Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, 77030 4009, USA
    J Urol 171:145-8. 2004
    ..The role of surgery for metastatic disease is not well established for urothelial cancer, but is sometimes undertaken in the face of persistent or recurrent disease that can be surgically resected...
  42. ncbi request reprint Bayesian and frequentist two-stage treatment strategies based on sequential failure times subject to interval censoring
    Peter F Thall
    Department of Biostatistics, University of Texas, Houston, TX, USA
    Stat Med 26:4687-702. 2007
    ..Advantages and disadvantages of this design compared to standard methods are discussed...
  43. ncbi request reprint Dasatinib inhibits both osteoclast activation and prostate cancer PC-3-cell-induced osteoclast formation
    John C Araujo
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Cancer Biol Ther 8:2153-9. 2009
    ..Since Src kinase has been shown to be necessary for osteoclast function, we hypothesized that dasatinib, a Src family kinase inhibitor, would reduce osteoclast activity and prostate cancer (PC-3) cell-induced osteoclast formation...
  44. pmc Inhibition of RNA-dependent protein kinase (PKR) leads to cancer cell death and increases chemosensitivity
    Abujiang Pataer
    Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Biol Ther 8:245-52. 2009
    ..Our results suggest a rationale to develop therapeutic strategies that target PKR signaling in human cancer cells...
  45. ncbi request reprint Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases
    Paul Mathew
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 13:5816-24. 2007
    ....
  46. ncbi request reprint Glycogen synthase kinase-3 beta is involved in the phosphorylation and suppression of androgen receptor activity
    Thomas R Salas
    Department of Clinical Cancer Prevention, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Biol Chem 279:19191-200. 2004
    ....
  47. pmc GWAS meets microarray: are the results of genome-wide association studies and gene-expression profiling consistent? Prostate cancer as an example
    Ivan P Gorlov
    Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    PLoS ONE 4:e6511. 2009
    ..It is not obvious whether there is a consistency between the candidate genes identified by GWAS (GWAS genes) and those identified by profiling gene expression (microarray genes)...
  48. doi request reprint Phase I study of concurrent weekly docetaxel and repeated samarium-153 lexidronam in patients with castration-resistant metastatic prostate cancer
    Shi Ming Tu
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, 77239 1439, USA
    J Clin Oncol 27:3319-24. 2009
    ..We evaluated the safety and feasibility of a concurrent combination of weekly docetaxel with repeated (153)Sm-lexidronam in patients with castration-resistant prostate cancer (CRPC)...
  49. pmc Soluble ErbB3 levels in bone marrow and plasma of men with prostate cancer
    Sue Hwa Lin
    Department of Molecular Pathology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Cancer Res 14:3729-36. 2008
    ..We aimed to understand clinical implications of sErbB3 by establishing an ELISA to detect sErbB3 levels in bone marrow and plasma samples...
  50. pmc Cadherin-11 promotes the metastasis of prostate cancer cells to bone
    Khoi Chu
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Mol Cancer Res 6:1259-67. 2008
    ..Cadherin-11 expression was not detected in metastatic lesions that occur in other organs. Collectively, these findings suggest that cadherin-11 is involved in the metastasis of prostate cancer cells to bone...
  51. ncbi request reprint A Phase I/II study of strontium-89 combined with gemcitabine in the treatment of patients with androgen independent prostate carcinoma and bone metastases
    Lance C Pagliaro
    Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 97:2988-94. 2003
    ..The objectives of the current study were to determine the maximum tolerated dose and to evaluate the efficacy of gemcitabine given in combination with strontium-89 to patients with androgen independent prostate carcinoma...
  52. ncbi request reprint Treating refractory advanced or metastatic urothelial carcinoma with interleukin-2: a phase II study
    Jeri Kim
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Box 427, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Urol Oncol 21:21-6. 2003
    ..8 to 17.1 months), with a 15.9-month median survival for 3 patients with poor performance status and visceral metastases. Further clinical investigation of the biological effect of IL-2 in urothelial carcinoma may be warranted...
  53. ncbi request reprint Multimodality therapy: bone-targeted radioisotope therapy of prostate cancer
    Shi Ming Tu
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Adv Hematol Oncol 8:341-51. 2010
    ....
  54. ncbi request reprint Thalidomide/estramustine/paclitaxel in metastatic androgen-independent prostate cancer
    Paul Mathew
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Clin Genitourin Cancer 5:144-9. 2006
    ..This is a phase I/II trial of thalidomide with estramustine and paclitaxel in men with androgen-independent prostate cancer (AIPC) who underwent previous chemotherapy...
  55. ncbi request reprint The association of p21((WAF-1/CIP1)) with progression to androgen-independent prostate cancer
    Karim Fizazi
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 8:775-81. 2002
    ..Another explanation involves the regulation of p21 expression by the androgen receptor, which also suggests that p21 may have antiapoptotic function in prostate cancer...
  56. ncbi request reprint Cisplatin, gemcitabine, and ifosfamide as weekly therapy: a feasibility and phase II study of salvage treatment for advanced transitional-cell carcinoma
    Lance C Pagliaro
    Department of Genitourinary Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    J Clin Oncol 20:2965-70. 2002
    ....
  57. ncbi request reprint Docetaxel in the integrated management of prostate cancer. Current applications and future promise
    Christopher J Logothetis
    Department of Genitourinary Medical Oncology, The University of Texas, M D Anderson Cancer Center, Houston 77030, USA
    Oncology (Williston Park) 16:63-72. 2002
    ..These types of investigational studies will likely occupy a dominant position in future research initiatives for patients with advanced prostate cancer...
  58. ncbi request reprint Androgen receptor polymorphisms and risk of biochemical failure among prostatectomy patients
    Sara S Strom
    Department of Epidemiology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Prostate 60:343-51. 2004
    ..Little is known about the role of inherited genotypes in prostate cancer (PC) progression. This prospective study evaluated the predictive value of androgen receptor (AR) polymorphisms (CAG and GGC repeats) among prostatectomy patients...
  59. pmc Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer
    Randall E Millikan
    Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, 1155 Pressler, CPB7 3462, Houston, TX 77030, USA
    J Clin Oncol 26:5936-42. 2008
    ....
  60. ncbi request reprint Obesity, weight gain, and risk of biochemical failure among prostate cancer patients following prostatectomy
    Sara S Strom
    Department of Epidemiology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 11:6889-94. 2005
    ....
  61. ncbi request reprint Therapy tolerance in selected patients with androgen-independent prostate cancer following strontium-89 combined with chemotherapy
    Shi Ming Tu
    Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, 77030, USA
    J Clin Oncol 23:7904-10. 2005
    ..We assessed the rate of bone marrow failure in patients with prostate cancer who had received a dose of strontium-89...
  62. ncbi request reprint Evidence that transfer of functional p53 protein results in increased apoptosis in prostate cancer
    Louis L Pisters
    Department of Urology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 10:2587-93. 2004
    ..This study was undertaken to determine the safety of INGN 201 in patients with locally advanced prostate cancer, to assess transgene expression, and to evaluate antitumoral activity...
  63. pmc Neuroendocrine prostate cancer xenografts with large-cell and small-cell features derived from a single patient's tumor: morphological, immunohistochemical, and gene expression profiles
    Ana Aparicio
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Prostate 71:846-56. 2011
    ..Large-cell neuroendocrine carcinoma (LCNEC) is a much rarer variant that behaves similarly to SCC. The biological mechanisms that drive these disease variants are poorly understood...
  64. doi request reprint Targeting Src signaling in metastatic bone disease
    John Araujo
    MD Anderson Cancer Center, Houston, TX 77030 3721, USA
    Int J Cancer 124:1-6. 2009
    ..Because of the role of Src in both cancer development and in bone metabolism, it may provide a therapeutic target for patients with bone metastases...
  65. ncbi request reprint Combined laser capture microdissection and serial analysis of gene expression from human tissue samples
    Jeong Hee Cho-Vega
    Department of Molecular Pathology, The University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA
    Mod Pathol 18:577-84. 2005
    ....
  66. ncbi request reprint Identification of cell cycle regulatory genes as principal targets of p53-mediated transcriptional repression
    Kevin B Spurgers
    Department of Molecular Pathology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Biol Chem 281:25134-42. 2006
    ..g. p21) but also the repression of targets that regulate proliferation at several distinct phases of the cell cycle...
  67. ncbi request reprint p21 modulates threshold of apoptosis induced by DNA-damage and growth factor withdrawal in prostate cancer cells
    Luis A Martinez
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Carcinogenesis 23:1289-96. 2002
    ..These observations may thus provide implications onto the integration of chemotherapy and androgen ablation...
  68. pmc Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial
    Bradley C Carthon
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 16:2861-71. 2010
    ..Our group conducted the first preoperative clinical trial with the anti-CTLA-4 antibody ipilimumab in 12 patients with localized urothelial carcinoma of the bladder...
  69. ncbi request reprint Combinatorial screenings in patients: the interleukin-11 receptor alpha as a candidate target in the progression of human prostate cancer
    Amado J Zurita
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Res 64:435-9. 2004
    ..Moreover, our results illustrate the ability of direct combinatorial screening systems in cancer patients for identification of relevant targets in the context of human disease...
  70. ncbi request reprint Targeting prostate cancer bone metastases
    Christopher Logothetis
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 97:785-8. 2003
  71. pmc CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients
    Chrysoula I Liakou
    Department of Genitourinary Medical Oncology, M D Anderson Cancer Center, University of Texas, Houston, TX 77030, USA
    Proc Natl Acad Sci U S A 105:14987-92. 2008
    ....
  72. ncbi request reprint Stem-cell origin of metastasis and heterogeneity in solid tumours
    Shi Ming Tu
    Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Lancet Oncol 3:508-13. 2002
    ..Further investigation of the role of stem cells in the development of cancer may lead to the discovery of novel diagnostic tools, prognostic markers, and therapeutic targets in the battle against cancer...
  73. pmc Cadherin-11 increases migration and invasion of prostate cancer cells and enhances their interaction with osteoblasts
    Chih Fen Huang
    Departments of Molecular Pathology, Genitourinary Medical Oncology, and System Biology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Cancer Res 70:4580-9. 2010
    ..These observations suggest that cadherin-11 not only provides a physical link between PCa cells and osteoblasts but also increases PCa cell motility and invasiveness that may facilitate the metastatic colonization of PCa cells in bone...
  74. pmc Inverse relationship between 15-lipoxygenase-2 and PPAR-gamma gene expression in normal epithelia compared with tumor epithelia
    Vemparala Subbarayan
    Department of Clinical Cancer Prevention, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Neoplasia 7:280-93. 2005
    ..These results suggest that feedback mechanisms may contribute to the loss of 15-LOX-2 pathway components, which coincide with an increase in PPAR-gamma in many epithelial cancers...
  75. ncbi request reprint Review of late complications of treatment and late relapse in testicular cancer
    Eleni Efstathiou
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Natl Compr Canc Netw 4:1059-70. 2006
    ..Although current treatment of advanced disease has changed its natural course, we are challenged by an increasing incidence of late relapse, an entity with a distinct tumor biology characterized by latency and chemoresistance...
  76. ncbi request reprint Fingerprinting the circulating repertoire of antibodies from cancer patients
    Paul J Mintz
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Nat Biotechnol 21:57-63. 2003
    ..Exploiting the differential humoral response to cancer through such an approach may identify molecular markers and targets for diagnostic and therapeutic intervention...
  77. ncbi request reprint 5α-reductase inhibitors for prostate-cancer prevention
    Jeri Kim
    University of Texas M D Anderson Cancer Center, Houston, TX
    N Engl J Med 365:2340. 2011
    ..7% with finasteride . . ...
  78. pmc Prognostic factors for survival among Caucasian, African-American and Hispanic men with androgen-independent prostate cancer
    Reena B Wyatt
    Department of Urology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 446, Houston, TX 77030, USA
    J Natl Med Assoc 96:1587-93. 2004
    ..The objective of the current study was to define if race was an independent prognostic factor among other variables assessed for survival among men treated for androgen independent prostate cancer...
  79. ncbi request reprint Improved tolerability and quality of life with maintained efficacy using twice-daily low-dose interferon-alpha-2b: results of a randomized phase II trial of low-dose versus intermediate-dose interferon-alpha-2b in patients with metastatic renal cell carci
    Nizar M Tannir
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 107:2254-61. 2006
    ..In a randomized Phase II trial, the authors tested the hypothesis that twice-daily low-dose IFN is more effective than daily intermediate-dose IFN in patients with metastatic renal cell cancer (MRCC)...
  80. ncbi request reprint Prostate carcinoma with testicular or penile metastases. Clinical, pathologic, and immunohistochemical features
    Shi Ming Tu
    Department of Genitourinary Medical Oncology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Cancer 94:2610-7. 2002
    ..Despite the proximity, prostate carcinoma seldom metastasizes to the penis or testis...
  81. doi request reprint Housekeeping genes in prostate tumorigenesis
    Jinyoung Byun
    Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 4009, USA
    Int J Cancer 125:2603-8. 2009
    ..The results of these analyses suggest that during prostate tumorigenesis, there is a period when the tumor is under cellular stress and, therefore, may be the most vulnerable and responsive to treatment...
  82. doi request reprint Chemotherapy for advanced prostate cancer: 25 years later
    Christopher J Logothetis
    The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    J Clin Oncol 26:2423-4. 2008
  83. ncbi request reprint Suppression of prostate tumor cell growth by stromal cell prostaglandin D synthase-derived products
    Jeri Kim
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Res 65:6189-98. 2005
    ....
  84. ncbi request reprint Differential peroxisome proliferator-activated receptor-gamma isoform expression and agonist effects in normal and malignant prostate cells
    Vemparala Subbarayan
    Department of Clinical Cancer Prevention, University of Texas M D Anderson Cancer Center, Unit 236, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Cancer Epidemiol Biomarkers Prev 13:1710-6. 2004
    ..These findings have important implications for the development of PPAR-gamma-targeting agents that prevent or treat prostate cancer and spare normal prostate cells...
  85. pmc Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human bladder cancer
    Chrysoula I Liakou
    Department of Genitourinary Medical Oncology, University of Texas, M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Immun 7:10. 2007
    ..This review will focus on immunological responses to bladder cancer and ongoing studies to identify factors that are amenable to therapeutic manipulation...
  86. doi request reprint Adipose tissue-derived stem cells promote prostate tumor growth
    Lukas Prantl
    Department of Molecular Pathology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Prostate 70:1709-15. 2010
    ..While most knowledge has been derived from studies of breast cancer cells, little is known regarding the influence of tissue resident stem cells on the tumor biology of prostate cancer...
  87. doi request reprint Strategy for the application of therapy in prostate cancer
    Christopher J Logothetis
    Department of GU Medical Oncology UT, MD Anderson Cancer Center, Houston, TX, USA
    Adv Exp Med Biol 617:193-9. 2008
  88. ncbi request reprint Enhanced suppression of prostate tumor growth by combining C-CAM1 gene therapy and angiogenesis inhibitor TNP-470
    Yeong Shiau Pu
    Department of Urology, National Taiwan University College of Medicine, Taipei, Taiwan 100, ROC
    Anticancer Drugs 13:743-9. 2002
    ..The novel strategy may have clinical implications for the treatment of prostate cancer...
  89. ncbi request reprint Pathogenesis and treatment of prostate cancer bone metastases: targeting the lethal phenotype
    Robert D Loberg
    University of Michigan, Ann Arbor, MI, USA
    J Clin Oncol 23:8232-41. 2005
    ..Here, we review the current therapeutic strategies for targeting the prostate cancer-bone microenvironment and several single- and multiagent targeted approaches to the treatment of advanced prostate cancer that are under development...
  90. ncbi request reprint Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data
    Karim Fizazi
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    Lancet Oncol 8:994-1000. 2007
    ..We aimed to assess whether combining estramustine with chemotherapy increases survival in patients with castration-refractory prostate cancer...
  91. ncbi request reprint Challenge of locally persistent prostate cancer: an unresolved clinical dilemma
    Christopher J Logothetis
    J Clin Oncol 20:3187. 2002

Research Grants1

  1. University of Texas SPORE in Prostate Cancer
    Christopher Logothetis; Fiscal Year: 2007
    ..The achievement of the aims of this Prostate Cancer SPORE proposal will contribute to the development of effective treatments for patients with prostate cancer. ..